Supplementary Table 2. Cohort characteristics, rifaximin *vs.* no-rifaximin, after propensity score matching

Characteristic	No rifaximin (n=679)	Rifaximin (n=679)	*P*-value	SMD
Age (yr)	57.00 [46.00, 66.00]	55.00 [46.00, 64.00]	0.167	0.054
Male sex	430 (63.3)	458 (67.5)	0.124	0.087
World Bank income group classification			<0.001	0.313
High	217 (32.0)	208 (30.6)		
Upper middle	278 (40.9)	196 (28.9)		
Low/low-middle	184 (27.1)	275 (40.5)		
Etiology				
Alcohol	294 (43.3)	315 (46.4)	0.275	0.062
MASLD	144 (21.2)	158 (23.3)	0.396	0.05
Hepatitis B	94 (13.8)	65 (9.6)	0.018	0.133
Hepatitis C	73 (10.8)	74 (10.9)	>0.999	0.005
Auto-immune liver diseases	39 (5.7)	43 (6.3)	0.733	0.025
Cryptogenic	52 (7.7)	49 (7.2)	0.836	0.017
Other	28 (4.1)	25 (3.7)	0.779	0.023
Comorbidities				
Diabetes	222 (32.7)	234 (34.5)	0.527	0.037
Hypertension	170 (25.0)	162 (23.9)	0.659	0.027
Hyperlipidemia	86 (12.7)	85 (12.5)	>0.999	0.004
Cirrhosis related history				
Prior ascites	534 (78.6)	564 (83.1)	0.045	0.112
Prior variceal bleed	213 (31.4)	244 (35.9)	0.085	0.097
Prior hepatic encephalopathy	292 (43.0)	441 (64.9)	<0.001	0.451
Prior hyponatremia	170 (25.0)	232 (34.2)	<0.001	0.201
Prior acute kidney injury/HRS	174 (25.6)	234 (34.5)	<0.001	0.194
Hospitalized in past 6 mo	72 (10.6)	79 (11.6)	0.605	0.033
Infections in past 6 mo	389 (57.3)	427 (62.9)	0.04	0.114
Prior listing for liver transplant	239 (35.2)	270 (39.8)	0.093	0.094
Medications on admission				
Β-blockers	241 (35.5)	270 (39.8)	0.117	0.088
Diuretics	446 (65.7)	456 (67.2)	0.605	0.031
Lactulose	546 (80.4)	603 (88.8)	<0.001	0.234
SBP prophylaxis	123 (18.1)	187 (27.5)	<0.001	0.226
Statins	58 (8.5)	65 (9.6)	0.571	0.036
Proton-pump inhibitors	354 (52.1)	399 (58.8)	0.016	0.134
HBV antivirals	102 (15.0)	87 (12.8)	0.272	0.064
Admission reasons				
Infection	393 (57.9)	387 (57.0)	0.784	0.018
Liver related	600 (88.4)	613 (90.3)	0.292	0.062
Non-liver related	21 (3.1)	14 (2.1)	0.304	0.065
Admission labs				
Hemoglobin	9.70 [8.10, 11.50]	9.40 [8.00, 10.90]	0.032	0.108
WBC	8.20 [4.96, 12.26]	8.05 [4.90, 12.60]	0.861	0.088
INR	1.70 [1.39, 2.20]	1.82 [1.47, 2.40]	0.001	0.064

 https://doi.org/10.3350/cmh.2026.0228

Supplementary Table 2. Continued

Characteristic	No rifaximin (n=679)	Rifaximin (n=679)	*P*-value	SMD
Sodium	133.00 [128.15, 137.00]	132.00 [128.00, 137.00]	0.255	0.065
Creatinine	1.11 [0.77, 1.98]	1.20 [0.80, 2.00]	0.229	0.055
Bilirubin	3.88 [1.63, 10.70]	4.76 [1.87, 12.28]	0.019	0.081
Albumin	2.66 [2.22, 3.10]	2.70 [2.30, 3.11]	0.481	0.001
MELD-Na	25.00 [19.00, 30.00]	26.00 [20.00, 32.00]	0.003	0.162
DRO details				
Any DRO	97 (14.3)	101 (14.9)	0.818	--
VRE-related DRO	14 (2.1)	13 (1.9)	>0.999	--
MRSA-related DRO	7 (1.0)	9 (1.3)	0.801	--
Fluoroquinolone DRO	25 (3.7)	27 (4.0)	0.888	--
Carbapenemase DRO	22 (3.2)	38 (5.6)	0.048	--
Outcomes				
In-hospital mortality	151 (22.2)	192 (28.3)	0.012	--
Mortality or hospice discharge	168 (24.7)	197 (29.0)	0.087	--
In-hospital transplant	30 (4.4)	26 (3.9)	0.72	--
ICU transfer	203 (29.9)	266 (39.2)	<0.001	--
Hospital LOS	12.00 [7.00, 21.00]	11.00 [7.00, 19.00]	0.155	--
30-Day readmission	138 (30.7)	128 (30.3)	0.937	--
30-Day mortality	204 (34.2)	221 (35.8)	0.588	--
30-Day transplant	43 (9.4)	44 (10.4)	0.704	--
Composite, death or DRO	214 (31.5)	258 (38.0)	0.014	--

DRO, drug-resistant organism; HBV, hepatitis B virus; HRS, hepatorenal syndrome; ICU, intensive care unit; INR, international normalized ratio; LOS, length of stay; MASLD, metabolic dysfunction associated liver disease; MELD-Na, Model for end-stage liver disease; MRSA, methicillin-resistant *Staphylococcus aureus*; SBP, spontaneous bacterial peritonitis; SMD, standardized mean difference; VRE, vancomycin resistant Enterococcus; WBC, white blood cell count.